Why the study?
Does the withdrawal of short-acting oral nifedipine jeopardize the treatment of acute severe hypertension in pregnant women?
Does the withdrawal of short-acting oral nifedipine jeopardize the treatment of acute severe hypertension in pregnant women?
Answers are grounded in this paper and cite their sources.
The withdrawal of short-acting oral nifedipine in Australia due to adverse effects in non-pregnant patients may negatively impact the management of acute severe hypertension in pregnancy.
Short-acting oral nifedipine has been withdrawn from the Australian market because of reports of its adverse effects after long-term treatment in non-pregnant patients with heart disease. This will have a major impact on the treatment of acutely hypertensive pregnant women, in whom the drug has proven to be safe, effective and easy to administer. Should pregnant women be forced to use less suitable agents, thus threatening their own and their babies' health?
No takes yet. Share an insight, caveat, or question.
Brown et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: